Want to see TSE:KNE full AI Analyst Report?
KNE Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EDT
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.05
Previous CloseN/A
Volume17.00K
Average Volume (3M)112.95K
Market Cap
C$5.13M
Enterprise ValueC$6.98
Total Cash (Recent Filing)C$395.06K
Total Debt (Recent Filing)C$1.92M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding205,056,560
10 Day Avg. Volume120,057
30 Day Avg. Volume112,955
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-8.69
Price to Sales (P/S)15.17
P/FCF Ratio-1.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform & Diversified Revenue ModelKane's anti-biofilm platform spans product sales, licensing/royalties and collaborations across wound care, animal health and industrial uses. This multi-channel, IP-driven model provides durable optionality and scaling pathways if adoption and partner monetization progress over quarters.
Debt Reduction / DeleveragingMaterial reduction in debt versus 2023 improves financial flexibility and lowers refinancing pressure. Reduced leverage diminishes interest and covenant risk, giving management more runway to execute commercialization and R&D initiatives without immediate financing constraints.
Improving Cash Burn TrendReported improvement in cash burn and FCF tracking net losses indicate better cost control and operational discipline. A continued downward trend in cash outflows extends runway, making a path to break-even and sustained operations more feasible over the medium term.
Bears Say
Severe Revenue Decline & Negative Gross MarginAn ~86% TTM revenue collapse combined with negative gross margin shows core product economics currently lose money. This undermines pricing power, channel presence and fixed-cost absorption; reversing it requires sustained revenue recovery or structural margin improvements.
Negative Shareholders' EquityNegative equity (~-$1.4M TTM) constrains financing options and heightens dilution risk. It can limit access to traditional debt, force equity raises on dilutive terms, and restrict strategic investments or partnerships that require stronger balance-sheet metrics.
Persistent Negative Operating Cash FlowConsistently negative OCF and FCF reflect ongoing cash burn and dependence on external funding. This persistent outflow increases execution and refinancing risk, potentially diverting management focus to capital raises and limiting sustainable investment in commercialization or R&D.
KNE FAQ
What was Kane Biotech Inc’s price range in the past 12 months?
Kane Biotech Inc lowest stock price was C$0.02 and its highest was C$0.05 in the past 12 months.
What is Kane Biotech Inc’s market cap?
Kane Biotech Inc’s market cap is C$5.13M.
When is Kane Biotech Inc’s upcoming earnings report date?
Kane Biotech Inc’s upcoming earnings report date is Aug 27, 2026 which is in 26 days.
How were Kane Biotech Inc’s earnings last quarter?
Currently, no data Available
Is Kane Biotech Inc overvalued?
According to Wall Street analysts Kane Biotech Inc’s price is currently Overvalued.
Does Kane Biotech Inc pay dividends?
Kane Biotech Inc does not currently pay dividends.
What is Kane Biotech Inc’s EPS estimate?
Kane Biotech Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kane Biotech Inc have?
Kane Biotech Inc has 205,056,560 shares outstanding.
What happened to Kane Biotech Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kane Biotech Inc?
Currently, no hedge funds are holding shares in TSE:KNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kane Biotech Inc
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
Technical Analysis
―
XORTX Therapeutics Inc
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―